臨床外科70巻4号

2015年04月発行

特集 膵・消化管神経内分泌腫瘍（GEP-NET）のアップデート

GEP-NETの薬物療法の現状と今後の展望

著者： 奥山浩之¹ 池田公史¹ 高橋秀明¹ 土井綾子² 坂東英明² 岡本渉² 吉野孝之²

所属機関： ¹独立行政法人国立がん研究センター東病院肝胆膵内科 ²独立行政法人国立がん研究センター東病院消化管内科

ページ範囲：P.450 - P.455

【ポイント】
◆NETのホルモン症状の緩和および腫瘍制御には，ソマトスタチンアナログが有用である．
◆切除不能NET G1，G2に対して，腫瘍量や進行度に応じて，細胞障害性抗癌剤や分子標的治療薬が用いられる．
◆NEC（神経内分泌癌）に対しては，小細胞肺癌に準じてプラチナベースのレジメンが選択されることが多い．

参考文献

1）Rinke A, Muller HH, Schade-Brittinger C, et al：Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors：a report from the PROMID Study Group. J Clin Oncol 27：4656-4663, 2009

2）Caplin ME, Pavel M, Cwikla JB, et al：Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371：224-233, 2014

3）Moertel CG, Lefkopoulo M, Lipsitz S, et al：Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326：519-523, 1992

4）Kouvaraki MA, Ajani JA, Hoff P, et al：Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22：4762-4771, 2004

5）Sun W, Lipsitz S, Catalano P, et al；Eastern Cooperative Oncology Group：Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors：Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23：4897-4904, 2005

6）独立行政法人医薬品医療機器総合機構ホームページ．医療用医薬品の承認審査情報，ザノサー点滴静注用1g審議結果報告書［http://www.info.pmda.go.jp/shinyaku/P201400139/620095000_22600AMX01315_A100_2.pdf］

7）Ramanathan RK, Cnaan A, Hahn RG, et al：Phase II trial of dacarbazine（DTIC）in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 12：1139-1143, 2001

8）Ekeblad S, Sundin A, Janson ET, et al：Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13：2986-2991, 2007

9）Strosberg JR, Fine RL, Choi J, et al：First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117：268-275, 2011

10）Bukowski RM, Tangen CM, Peterson RF, et al：Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer 73：1505-1508, 1994

11）Kulke MH, Stuart K, Enzinger PC, et al：Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24：401-406, 2006

12）Raymond E, Dahan L, Raoul JL, et al：Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364：501-513, 2011

13）Yao JC, Shah MH, Ito T, et al：Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364：514-523, 2011

14）Pavel ME, Hainsworth JD, Baudin E, et al：Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome（RADIANT-2）：a randomised, placebo-controlled, phase 3 study. Lancet 378：2005-2012, 2011

15）Ahn HK, Choi JY, Kim KM, et al：Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours. Br J Cancer 109：1414-1419, 2013

16）Hobday TJ, Qin R, Reidy-Lagunes D, et al：Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. J Clin Oncol 2014

17）Pavel M, Baudin E, Couvelard A, et al：ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95：157-176, 2012

18）Oberg K, Knigge U, Kwekkeboom D, et al：Neuroendocrine gastro-entero-pancreatic tumors：ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23（Suppl 7）：vii124-130, 2012

19）National Comprehensive Cancer Network（NCCN）. Neuroendocrine Tumors 2015［http://www.nccn.org］

20）Ramage JK, Ahmed A, Ardill J, et al：Guidelines for the management of gastroenteropancreatic neuroendocrine（including carcinoid）tumours（NETs）. Gut 61：6-32, 2012

21）Sorbye H, Welin S, Langer SW, et al：Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma（WHO G3）：the NORDIC NEC study. Ann Oncol 24：152-160, 2013

22）Shida T, Kishimoto T, Furuya M, et al：Expression of an activated mammalian target of rapamycin（mTOR）in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol 65：889-893, 2010